Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

Phase 1

Completed

• Conditions: Bacterial Infections; HIV Infections

• Registration Number: NCT00002139
• Lead Sponsor: Pfizer

Brief Summary

To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.

Detailed Description

Patients are randomized to receive azithromycin orally or intravenously, with crossover to the alternate treatment after a 21-day wash-out period.

Study Timeline

• Status Verified: 1996-04
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Ctr for Phase I Research; 🇺🇸 Wichita, Kansas, United States